StreetInsider.com News Articles

Retension Pharmaceuticals prices IPO at $12 per share on Nasdaq

Thu, 08 Oct 2026 21:36:11 -0400

Retension Pharmaceuticals, Inc. (Nasdaq: RTSN), a clinical-stage biopharmaceutical company, priced its initial public offering of 3,750,000 shares of common stock at $12.00 per share, according to a press release issued Oct. 8, 2026.

The offering is expected to generate $45.0 million in gross proceeds before underwriting discounts, commissions, and other expenses. Retension has granted underwriters a 30-day option to purchase up to an additional 562,500 shares at the IPO price, less underwriting discounts and commissions.

Shares were expected to begin trading on the Nasdaq Capital Market on Oct. 9, 2026, under the ticker symbol "RTSN," with the offering expected to close on

Retension Pharmaceuticals prices IPO at $12 per share on Nasdaq

Thu, 08 Oct 2026 21:36:11 -0400

Shares were expected to begin trading on the Nasdaq Capital Market on Oct. 9, 2026, under the ticker symbol "RTSN," with the offering expected to close on

Retension Pharmaceuticals prices IPO at $12 per share on Nasdaq

Thu, 08 Oct 2026 21:35:57 -0400

The offering is expected to generate $45.0 million in gross proceeds before underwriting discounts, commissions, and other expenses. Retension has also granted underwriters a 30-day option to purchase up to an additional 562,500 shares at the IPO price.

Shares are expected to begin trading on the Nasdaq Capital Market on Oct. 9, 2026, under the ticker symbol "RTSN," with the offering expected to close on or about Oct. 13,

Retension Pharmaceuticals prices IPO at $12 per share on Nasdaq

Thu, 08 Oct 2026 21:35:57 -0400

Shares are expected to begin trading on the Nasdaq Capital Market on Oct. 9, 2026, under the ticker symbol "RTSN," with the offering expected to close on or about Oct. 13,

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

Thu, 08 Oct 2026 21:35:44 -0400

FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today the pricing of its upsized initial public offering of 3,750,000 shares of its common stock at an initial public offering price of $12.00 per share. The gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $45.0 million. All shares of common stock are being offered

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

Thu, 08 Oct 2026 21:35:44 -0400

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

Thu, 08 Oct 2026 21:35:00 -0400

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

Thu, 08 Oct 2026 21:35:00 -0400